The Camrelizumab of Hengrui has been approved for 6 indications of 5 big cancer types

On April 29, 2021, Camrelizumab was approved by NMPA for treatment of nasopharyngeal carcinoma (NPC), in patients with advanced nasopharyngeal carcinoma whose disease has progressed or is intolerable after prior second-line chemotherapy or higher.In June of the same year, another news of victory was reported for Camrelizumab, which was approved by NMPA for first-line treatment of patients with locally recurrent or metastatic nasopharyngeal carcinoma in combination with cisplatin and gemcitabine. This is the world’s first PD-1 drug approved for first-line nasopharyngeal carcinoma indications. This is the 6th indication for which Camrelizumab has been approved, following Hodgkin's lymphoma, liver cancer, lung cancer, esophageal squamous carcinoma, and second-line and higher nasopharyngeal carcinoma.

SINOVAC Sabin strain of inactivated poliomyelitis vaccine was approved for marketing

The Sabin strain of inactivated poliomyelitis vaccine (“sIPV”) developed by Sinovac Biotech Co., Ltd. has obtained the drug registration approval issued by National Medical Products Administration on July 12, 2021, and it would be supplied to the market within the year.SINOVAC's sIPV is an inactivated vaccine, which may not pose a risk of paralysis (VAPP) throughout the course of vaccination, and the inoculator may not excrete active poliovirus into the external environment through the digestive tract, so there is no risk of morbidity due to the survival and mutation of the vaccine strain in the external environment.Since the beginning of developing sIPV,  SINOVAC has focused on the global polio eradication initiative, applying the world-leading technology and using the international standards to develop and manufacture the vaccine. The vaccine contains no preservatives or antibiotics, thus reducing the risk of occurrence of associated adverse reactions.